[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-407532-105":59,"doc-detail-407532-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","implementation-of-established-conditions-and-use-of-quality-by-design-principles-during-drug-development-status-in-the-us-eu-and-japan","Implementation of Established Conditions and Use of Quality by Design Principles during Drug Development - Status in the US, EU, and Japan","","Survey results from the Japan Pharmaceutical Manufacturers Association (JPMA) assess how Established Conditions (ECs) under ICH Q12 are used during drug development across the US, EU, and Japan. ECs are set through the Quality by Design (QbD) approach and require an effective Pharmaceutical Quality System (PQS) aligned with ICH Q8 and Q10. QbD use rose to over 70% in Japan since 2021, yet EC adoption in NDA submissions remains limited due to missing legal frameworks and limited internal understanding.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/implementation-of-established-conditions-and-use-of-quality-by-design-principles-during-drug-development-status-in-the-us-eu-and-japan/407532/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/implementation-of-established-conditions-and-use-of-quality-by-design-principles-during-drug-development-status-in-the-us-eu-and-japan/407532.png","ImageObject",300,407,{"name":92,"@type":93},"Maya Linwood","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-06","2026-09-28",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What are Established Conditions (ECs) and how are they linked to QbD and PQS?","Question",{"text":112,"@type":113},"ECs can be set by companies developing new drugs using the Quality by Design (QbD) approach defined in ICH Q8, together with an effective Pharmaceutical Quality System (PQS) per ICH Q10.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Why is EC adoption still limited in New Drug Application (NDA) submissions?",{"text":117,"@type":113},"The survey indicates that EC use in NDA submissions remains low because of a lack of legal framework and insufficient internal understanding of ECs.",{"name":119,"@type":110,"acceptedAnswer":120},"How do regional differences affect change assessment and EC use after approval?",{"text":121,"@type":113},"The survey reports that Europe and the US view risk assessment for changes and ECs as consistent with an effective PQS, while Japan perceives a mismatch between change assessment and predetermined change categories at approval, suggesting Japan may adopt a hybrid risk-assessment option.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},407532,1791454063,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":4},962084928432,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Therapeutic Innovation & Regulatory Science (2026) 60:117–126 [https://doi.org/10.1007/s43441-025-00856-1](https://doi.org/10.1007/s43441-025-00856-1)  \nRESEARCH  \nImplementation of Established Conditions and Use of Quality by  \nDesign Principles during Drug Development: Status in the US, EU, and  \nJapan. Data from a Survey Conducted by the Japan Pharmaceutical Manufacturers Association (JPMA)  \nYoshio Nakayama1,11 · Sonoko Yamauchi2,11 · Kozue Shimizume3,11 · Akinobu Nakanishi4,11 · Maki Masuyama5,11 · Yasuyo Ozaki6,11 · Koji Nakamura7,11 · Makoto Fujikawa8,11 · Masatsugu Kobayashi9,11 · Yuji Kashitani10,12  \nReceived: 18 April 2025 / Accepted: 1 August 2025 / Published online: 21 August 2025 © The Author(s) 2025  \nAbstract  \nThe JPMA conducted a survey among its member companies regarding the use of Established Conditions (ECs) under ICH Q12 . ECs can be set by companies that develop new drugs using the Quality by Design (QbD) approach defined in ICH Q8 and have an effective Pharmaceutical Quality System (PQS) as per ICH Q10 . The survey revealed that while the use of QbD has increased, surpassing 70% in Japan since 2021, the adoption of ECs in New Drug Application (NDA) submissions remains low due to a lack of legal framework and internal understanding. More companies were using ECsin post-approval changes (PACs) compared to NDA submissions. The survey also found that companies prefer the existing systems in each region when determining the change category during change initiation. While Europe and the US believe that risk assessment of changes and ECs are consistent with an effective PQS, Japan perceives a mismatch between change assessment and predetermined change categories at the time of approval. This results in Japan willing to have an option applying the risk assessment at change control to reporting category evaluation. Considering these circumstances, it is anticipated that the use of ECs will gradually expand, primarily in PACs. The discrepancies in change procedures among countries may hinder a stable supply, so Japan should consider introducing change guidelines similar to those in Europe and the US to facilitate a hybrid approach to approvals that can accommodate the expanded use of ECs.  \nKeywords Post approval changes (PACs) · Established conditions (ECs) · ICH Q12 · Quality by design (QbD) · PQS (Pharmaceutical quality systems)  \nIntroduction  \nICH guidelines, Q8 [1], Q9 [2], and Q10 [3] are often referred to as the Q Trio Guidelines (after adding Q11 [4], it became the Q Quartet) . These guidelines were established by ICH  \n􀀍 Yoshio Nakayama [nakayama_yoshio@lilly.com](nakayama_yoshio@lilly.com)  \n1 Eli Lilly Japan K.K, 5-1-28 Isogami-dori, Chuo-ku, Kobe 651-0086, Japan  \n2 Kyowa Kirin Co., Ltd, Tokyo, Japan  \n3 Meiji Seika Pharma Co., Ltd, Tokyo, Japan  \n4 TEIJIN PHARMA LIMITED, Tokyo, Japan  \n5 MSD K.K, Tokyo, Japan  \nto: “Develop a harmonised pharmaceutical quality system applicable across the life cycle of the product emphasizing an integrated approach to quality risk management and science”. This vision was intended to ensure quality products and reliable supply to patients. ICH developed these  \n6 AstraZeneca K.K, Osaka, Japan  \n7 Torii Pharmaceutical Co., Ltd, Tokyo, Japan  \n8 DAIICHI SANKYO COMPANY, LIMITED, Tokyo, Japan  \n9 Sumitomo Pharma Co., Ltd., Osaka, Japan  \n10 Takeda Pharmaceutical Company Limited, Osaka, Japan  \n11 JPMA Regulatory Affairs Committee, General Regulatory Sub-Committee, Tokyo, Japan  \n12 JPMA Regulatory Affairs Committee, Tokyo, Japan  \nguidelines [5] to ensure product quality and stable supply. Proper interpretation and use of these guidelines makes it possible to systematically implement a risk-based approach to drug quality assurance, change management, and drug development.  \nThe use of Quality by Design (QbD) principles as established by ICH Q8 was initially limited [6, 7] and expanded when the ICH Points to Consider document for the implementation of ICH Q8/Q9/Q10 [8] wa","cbCaiiqE5Lpl4tdM","https://ap.wps.com/l/cbCaiiqE5Lpl4tdM","pdf",1088713,"English","# Abstract\n# Keywords\n# Introduction\n## Q Trio and Q Quartet guidelines\n## Implementation of ICH Q12 across countries\n# Strategy and Method","[{\"question\":\"What are Established Conditions (ECs) and how are they linked to QbD and PQS?\",\"answer\":\"ECs can be set by companies developing new drugs using the Quality by Design (QbD) approach defined in ICH Q8, together with an effective Pharmaceutical Quality System (PQS) per ICH Q10.\"},{\"question\":\"Why is EC adoption still limited in New Drug Application (NDA) submissions?\",\"answer\":\"The survey indicates that EC use in NDA submissions remains low because of a lack of legal framework and insufficient internal understanding of ECs.\"},{\"question\":\"How do regional differences affect change assessment and EC use after approval?\",\"answer\":\"The survey reports that Europe and the US view risk assessment for changes and ECs as consistent with an effective PQS, while Japan perceives a mismatch between change assessment and predetermined change categories at approval, suggesting Japan may adopt a hybrid risk-assessment option.\"}]","Implementation of Established Conditions and Use of Quality by Design Principles during Drug Development - Status in the US, EU, and Japan | PDF",1790574475,25]